What should you know about MSK-ACCESS liquid biopsy?

Cancer cells can release small DNA fragments into the bloodstream. A liquid biopsy uses a blood sample and laboratory sequencing to search for selected changes in that circulating tumour DNA. The report may identify an alteration that helps the team match a cancer with a targeted medicine or understand disease biology.

A negative result does not prove that no cancer-related change exists: there may be too little tumour DNA in the sample, or the alteration may not be included in the test. A blood test also does not always replace tissue biopsy, which can show the cells and their surrounding structure.

Ask why the test has been recommended and which treatment decision it may inform. Confirm whether a tissue sample is also needed, especially if the blood result is negative or unclear. Tell the team about current treatment and previous biopsy results so the findings can be interpreted in context.

The blood draw is usually straightforward, but the value of the result depends on the amount and quality of tumour DNA detected. Ask when the report is expected and who will explain any detected alteration.

The blood draw itself should not cause significant ongoing problems. Contact the clinic for bleeding that continues, increasing swelling or pain at the needle site, or signs of infection. Seek urgent help for fainting that does not settle, severe breathlessness, chest pain or rapidly worsening weakness.

What question is this test intended to answer? Which genes or alterations does it assess? If the result is negative, would tissue biopsy or another test still be needed? Could a detected change alter my treatment, monitoring or eligibility for a trial?